Taro Pharmaceutical Industries Ltd. (NYSE:TARO) is reporting second quarter earnings results on Wednesday 28th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.77 per share from $ 125.34 million in revenue.
For the full year, analysts predict revenues of $ 544.85 million, while looking forward to loss of $ 8.62 per share.
Previous Quarter Performance
Taro Pharmaceutical Industries Ltd. unwinded income for the first quarter of $ 0.76 per share, from the revenue of $ 117.63 million. The consensus estimates are income of $ 1.16 per share from $ 158.35 million in revenue. The bottom line results missed street analysts by $ 0.4 or 34.48 percent, at the same time, top line results fell short of analysts by $ 40.72 million or 25.72 percent.
Stock Performance
Shares of Taro Pharmaceutical Industries Ltd. traded up $ 1.73 or 2.88 percent on Tuesday, reaching $ 61.73 with volume of 81.70 thousand shares. Taro Pharmaceutical Industries Ltd. has traded high as $ 63.48 and has cracked $ 59.40 on the downward trend
According to the previous trading day, closing price of $ 61.73, representing a 11.21 % increase from the 52 week low of $ 53.95 and a 39.81 % decrease over the 52 week high of $ 99.69.
The company has a market capital of $ 2.36 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.
